| ILLUMINA INC. DL-,01 |
| USA |
| Gesundheit |
| US4523271090 / 927079 |
| ILU (Frankfurt) / ILMN (NASDAQ) |
| FRA:ILU, ETR:ILU, ILU:GR, NASDAQ:ILMN |
| S&P500 |
| http://www.illumina.com/ |
|
Illumina Inc. is a global genomics and life sciences company that develops DNA sequencing and array-based technologies used to analyze genetic variation and biological function. Its products and systems support research, clinical testing, and applied..
>Volltext.. |
| 39165.18 Mio. EUR |
| 40357.3 Mio. EUR |
| 4037.11 Mio. EUR |
| 1047.22 Mio. EUR |
| 740.96 Mio. EUR |
| 4.86 EUR |
| 2269.58 Mio. EUR |
| 934.06 Mio. EUR |
| 983.46 Mio. EUR |
| 0.74 |
| 8.28% |
| -32.36% |
| - |
| - |
| - |
| - |
| ILLUMINA |
| 29.10.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|